Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan
Objectives Older adults (OA) are at risk of morbidity and mortality from respiratory syncytial virus (RSV), a major cause of seasonal acute respiratory illness. The first RSV vaccine for OA (RSVPreF3 OA) was recently launched in Japan. With the already large and growing OA population in Japan, and l...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2410898 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141430859300864 |
|---|---|
| author | Akiko Mizukami Victor Preckler Frederik Verelst Taizo Matsuki Yufan Ho Daisuke Kurai Daniel Molnar |
| author_facet | Akiko Mizukami Victor Preckler Frederik Verelst Taizo Matsuki Yufan Ho Daisuke Kurai Daniel Molnar |
| author_sort | Akiko Mizukami |
| collection | DOAJ |
| description | Objectives Older adults (OA) are at risk of morbidity and mortality from respiratory syncytial virus (RSV), a major cause of seasonal acute respiratory illness. The first RSV vaccine for OA (RSVPreF3 OA) was recently launched in Japan. With the already large and growing OA population in Japan, and limited RSV treatments, prevention is key. The aim of this study was to assess the cost-effectiveness of introducing RSVPreF3 OA for Japanese adults aged ≥60 years.Methods A static multicohort Markov model was adapted to assess the cost-effectiveness of a single dose of RSVPreF3 OA versus no vaccination over a three-year time horizon. Deterministic and probabilistic sensitivity analyses were conducted to assess parameter uncertainty.Results RSVPreF3 OA vaccination prevented 1,008,499 cases and 6,840 deaths, with 109,119 quality-adjusted life-years (QALYs) gained. The incremental cost-effectiveness ratio was Japanese yen (JPY) 4,180,084/QALY gained from a payer perspective and JPY 4,041,917/QALY gained from a societal perspective (with productivity loss from RSV disease), thus vaccination was considered cost-effective. Base case results were robust to changes in sensitivity and scenario analyses.Conclusions RSVPreF3 OA vaccination for adults ≥60 years can provide substantial health benefits and is a cost-effective intervention to reduce the RSV burden in Japan. |
| format | Article |
| id | doaj-art-21fe23ab10d14f46b920820743b90801 |
| institution | Kabale University |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-21fe23ab10d14f46b920820743b908012024-12-04T09:49:47ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-0123198699610.1080/14760584.2024.2410898Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in JapanAkiko Mizukami0Victor Preckler1Frederik Verelst2Taizo Matsuki3Yufan Ho4Daisuke Kurai5Daniel Molnar6GSK, Tokyo, JapanGSK, Wavre, BelgiumGSK, Wavre, BelgiumGSK, Tokyo, JapanGSK, Singapore, SingaporeKyorin University School of Medicine, Tokyo, JapanGSK, Wavre, BelgiumObjectives Older adults (OA) are at risk of morbidity and mortality from respiratory syncytial virus (RSV), a major cause of seasonal acute respiratory illness. The first RSV vaccine for OA (RSVPreF3 OA) was recently launched in Japan. With the already large and growing OA population in Japan, and limited RSV treatments, prevention is key. The aim of this study was to assess the cost-effectiveness of introducing RSVPreF3 OA for Japanese adults aged ≥60 years.Methods A static multicohort Markov model was adapted to assess the cost-effectiveness of a single dose of RSVPreF3 OA versus no vaccination over a three-year time horizon. Deterministic and probabilistic sensitivity analyses were conducted to assess parameter uncertainty.Results RSVPreF3 OA vaccination prevented 1,008,499 cases and 6,840 deaths, with 109,119 quality-adjusted life-years (QALYs) gained. The incremental cost-effectiveness ratio was Japanese yen (JPY) 4,180,084/QALY gained from a payer perspective and JPY 4,041,917/QALY gained from a societal perspective (with productivity loss from RSV disease), thus vaccination was considered cost-effective. Base case results were robust to changes in sensitivity and scenario analyses.Conclusions RSVPreF3 OA vaccination for adults ≥60 years can provide substantial health benefits and is a cost-effective intervention to reduce the RSV burden in Japan.https://www.tandfonline.com/doi/10.1080/14760584.2024.2410898Adultscost-effectivenessJapanprefusion F protein vaccinerespiratory syncytial virus |
| spellingShingle | Akiko Mizukami Victor Preckler Frederik Verelst Taizo Matsuki Yufan Ho Daisuke Kurai Daniel Molnar Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan Expert Review of Vaccines Adults cost-effectiveness Japan prefusion F protein vaccine respiratory syncytial virus |
| title | Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan |
| title_full | Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan |
| title_fullStr | Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan |
| title_full_unstemmed | Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan |
| title_short | Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan |
| title_sort | cost effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion f protein vaccine rsvpref3 oa for adults ≥60 years old in japan |
| topic | Adults cost-effectiveness Japan prefusion F protein vaccine respiratory syncytial virus |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2024.2410898 |
| work_keys_str_mv | AT akikomizukami costeffectivenessanalysisofrespiratorysyncytialvirusvaccinationwiththeadjuvantedprefusionfproteinvaccinersvpref3oaforadults60yearsoldinjapan AT victorpreckler costeffectivenessanalysisofrespiratorysyncytialvirusvaccinationwiththeadjuvantedprefusionfproteinvaccinersvpref3oaforadults60yearsoldinjapan AT frederikverelst costeffectivenessanalysisofrespiratorysyncytialvirusvaccinationwiththeadjuvantedprefusionfproteinvaccinersvpref3oaforadults60yearsoldinjapan AT taizomatsuki costeffectivenessanalysisofrespiratorysyncytialvirusvaccinationwiththeadjuvantedprefusionfproteinvaccinersvpref3oaforadults60yearsoldinjapan AT yufanho costeffectivenessanalysisofrespiratorysyncytialvirusvaccinationwiththeadjuvantedprefusionfproteinvaccinersvpref3oaforadults60yearsoldinjapan AT daisukekurai costeffectivenessanalysisofrespiratorysyncytialvirusvaccinationwiththeadjuvantedprefusionfproteinvaccinersvpref3oaforadults60yearsoldinjapan AT danielmolnar costeffectivenessanalysisofrespiratorysyncytialvirusvaccinationwiththeadjuvantedprefusionfproteinvaccinersvpref3oaforadults60yearsoldinjapan |